Inventor · disambiguated record
Lee M. Nadler
Also filed as: NADLER LEE · NADLER LEE M
31 granted patents·11 pending applications·908 citations·filing 1985–2006
98Inventor score
Files withDANA FARBER CANCER INST INC27BRIGHAM & WOMENS HOSPITAL3HARVARD COLLEGE2BRIGHAM & WOMAN S HOSPITAL1DANA FARBER CANCER INST BRIGHA1
Top patents by PatentIndex Score
42 records- 0198US5942607AB7-2: a CTLA4/CD28 ligandDANA FARBER CANCER INST INC·Filed 1993·Granted Aug 24, 1999·106 cites·9 claims
- 0296US5861310ATumor cells modified to express B7-2 with increased immunogenicity and uses thereforDANA FARBER CANCER INST INC·Filed 1995·Granted Jan 19, 1999·97 cites·10 claims
- 0394US7619078B2Nucleic acid molecules encoding B7-1DANA FARBER CANCER INST INC·Filed 2006·Granted Nov 17, 2009·17 cites·6 claims
- 0494US6719972B1Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodiesREPLIGEN CORP·Filed 1994·Granted Apr 13, 2004·126 cites·11 claims
- 0593US6130316AFusion proteins of novel CTLA4/CD28 ligands and uses thereforeDANA FARBER CANCER INST INC·Filed 1994·Granted Oct 10, 2000·64 cites·69 claims
- 0689US7700102B2Nucleic acids encoding CD100 moleculesDANA FARBER CANCER INST INC·Filed 2002·Granted Apr 20, 2010·23 cites·6 claims
- 0789US6608180B2B7-specific antibodiesBRIGHAM & WOMENS HOSPITAL·Filed 2001·Granted Aug 19, 2003·12 cites·2 claims
- 0888US5858776ATumor cells with increased immunogenicity and uses thereforHARVARD COLLEGE·Filed 1993·Granted Jan 12, 1999·60 cites·18 claims
- 0987US7195758B2Methods of inducing a T cell mediated immune response by administering antigen presenting B cellsDANA FARBER CANCER INST INC·Filed 2002·Granted Mar 27, 2007·21 cites·5 claims
- 1087US6605279B2Therapeutic compositions for inhibiting the interactions of B7-1 and B7-2 with their natural ligandsGENETICS INST·Filed 1999·Granted Aug 12, 2003·43 cites·6 claims
- 1187US6218510B1B7-1 and B7-2 polypeptidesBRIGHAM & WOMAN S HOSPITAL·Filed 1994·Granted Apr 17, 2001·35 cites·12 claims
- 1285US6149905ATumor cells with increased immunogenicity and uses thereforDANA FARBER CANCER INST INC·Filed 1998·Granted Nov 21, 2000·32 cites·18 claims
- 1384US6294660B1Nucleic acids encoding B7-1 and B7-2 moleculesDANA FARBER CANCER INST BRIGHA·Filed 1995·Granted Sep 25, 2001·35 cites·16 claims
- 1482US6319709B1Tumor cells with increased immunogenicity and uses thereforHARVARD COLLEGE·Filed 1999·Granted Nov 20, 2001·24 cites·20 claims
- 1582US6084067ACTLA4/CD28 ligands and uses thereforDANA FARBER CANCER INST INC·Filed 1995·Granted Jul 4, 2000·31 cites·8 claims
- 1680US6576754B2CD100 antigen and uses thereforDANA FARBER CANCER INST INC·Filed 1995·Granted Jun 10, 2003·31 cites·4 claims
- 1778US7153934B2T cell costimulatory polypeptides containing alternative domainsBRIGHAM & WOMENS HOSPITAL·Filed 2001·Granted Dec 26, 2006·2 cites·4 claims
- 1878US6071716ADNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cellsDANA FARBER CANCER INST INC·Filed 1993·Granted Jun 6, 2000·34 cites·38 claims
- 1976US8026224B2Tumor cells with increased immunogenicity and uses therforDANA FARBER CANCER INST INC·Filed 2005·Granted Sep 27, 2011·1 cites·10 claims
- 2073US7459544B2Nucleic acids encoding B7-2 fusion proteinsGENETICS INST LLC·Filed 2003·Granted Dec 2, 2008·1 cites·8 claims
- 2172US6824779B1Methods for inhibiting the interaction of B7-2 with its natural ligandDANA FARBER CANCER INST INC·Filed 1999·Granted Nov 30, 2004·20 cites·47 claims
- 2271US6451305B1Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligandDANA FARBER CANCER INST INC·Filed 1995·Granted Sep 17, 2002·23 cites·12 claims
- 2369US6653444B1Polypeptides comprising a B7 extracellular domainDANA FARBER CANCER INST INC·Filed 1995·Granted Nov 25, 2003·15 cites·18 claims
- 2467US7385023B1Cancer immunotherapy and diagnosis using cytochrome P450 1B1UNIV BOSTON·Filed 2000·Granted Jun 10, 2008·3 cites·1 claims
- 2566US7592007B2Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodiesDANA FARBER CANCER INST INC·Filed 2003·Granted Sep 22, 2009·2 cites·4 claims
- 2666US2004192899A1B-7 domain-specific antibodiesBRIGHAM & WOMENS HOSPITAL·Filed 2003·Application pending·0 cites
- 2764US6465251B1Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporinDANA FARBER CANCER INST INC·Filed 1996·Granted Oct 15, 2002·23 cites·11 claims
- 2863US2003124103A1Tumor cells with increased immunogenicity and uses thereforFiled 2002·Application pending·0 cites
- 2961US7955845B2Modified antigen-presenting cellsDANA FARBER CANCER INST INC·Filed 2004·Granted Jun 7, 2011·0 cites·33 claims
- 3059US2002086421A1Tumor cells with increased immunogenicity and uses thereforUNIV MARYLAND·Filed 2001·Application pending·0 cites
- 3158US2004037808A1Methods for modulating T cell responses by manipulating a commom cytokine receptor gamma-chainDANA FARBER CANCER INST INC·Filed 2003·Application pending·0 cites
- 3257US2003170821A1DNA encoding B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cellsDANA FARBER CANCER INST INC·Filed 2002·Application pending·0 cites
- 3355US2005123596A1pH-triggered microparticlesFiled 2004·Application pending·0 cites
- 3454US2002182727A1Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cellsDANA FARBER CANCER INST INC·Filed 2002·Application pending·0 cites
- 3554US2006233795A1Methods for selectively modulating a Th2-type response within a population of activated CD4+ T cellsDANA FARBER CANCER INST INC·Filed 2006·Application pending·0 cites
- 3653US2002051784A1Methods for modulating T cell unresponsivenessDANA FARBER CANCER INST INC·Filed 2001·Application pending·0 cites
- 3752US6576236B1Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chainDANA FARBER CANCER INST INC·Filed 1994·Granted Jun 10, 2003·7 cites·11 claims
- 3849US6723705B1Tumor cells modified to express B7-2 with increased immunogenicity and uses thereforGENTICS INST INC·Filed 1998·Granted Apr 20, 2004·7 cites·25 claims
- 3949US2002127201A1Methods for inhibiting T cell responses by manipulating a common cytokine receptor gamma-chainDANA FARBER CANCER INST INC·Filed 2002·Application pending·0 cites
- 4049US2005129670A1Tumor cells modified to express B7-2 with increased immunogenicity and uses thereforDANA FARBER CANCER INST INC·Filed 2004·Application pending·0 cites
- 4144US4692405AMonoclonal antibodies to antigen on activated human B-cells and assay therefor, protein antigenic determinant therefor and method of making sameDANA FARBER CANCER INST INC·Filed 1985·Granted Sep 8, 1987·10 cites·22 claims
- 4236US7851591B1Cancer immunotherapy and diagnosis using universal tumor associated antigens, including hTERTDANA FARBER CANCER INST INC·Filed 1999·Granted Dec 14, 2010·3 cites·1 claims
Join the waitlist — get patent alerts
Get an alert when Lee M. Nadler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →